Weiss Ratings Reiterates Sell (E+) Rating for 10x Genomics (NASDAQ:TXG)

10x Genomics (NASDAQ:TXG)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

TXG has been the topic of a number of other research reports. Barclays reduced their price objective on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. Canaccord Genuity Group reduced their price target on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Morgan Stanley reduced their price target on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.57.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $12.10 on Wednesday. The stock has a market capitalization of $1.46 billion, a PE ratio of -7.96 and a beta of 1.85. The business has a fifty day moving average price of $14.44 and a two-hundred day moving average price of $17.19. 10x Genomics has a fifty-two week low of $10.80 and a fifty-two week high of $48.42.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, equities analysts expect that 10x Genomics will post -1.39 EPS for the current year.

Institutional Trading of 10x Genomics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC boosted its holdings in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after acquiring an additional 1,452 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of 10x Genomics in the fourth quarter worth $32,000. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics in the third quarter worth $35,000. Blue Trust Inc. boosted its holdings in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after acquiring an additional 1,025 shares during the period. Finally, Sound Income Strategies LLC raised its position in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after buying an additional 1,330 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.